

HeraCARE paid pilot commences with US-based Obstetrix Medical Group; leaders in women's and children's health care

- Paid pilot has commenced with Obstetrix Medical Group (Obstetrix), one of the largest clinical services providers specialising in women's and children's care in the U.S.
- Obstetrix and its affiliates partner with hospitals, health systems and health care facilities to offer care across more than 24 women's and children's specialties
- Upon completion of the pilot, both Obstetrix and HeraMED will seek to enter into a comprehensive agreement for wider deployment and scaled commercial implementation of the technology
- Discussions are underway to add additional Obstetrix-affiliated sites in due course
- Obstetrix is licensing the hardware and software from HeraMED on a SaaS-based per user, per month model for the pilot
- Pilot forms part of a potential rollout of the HeraCARE technology as a standard service for wider deployment and scaled commercial implementation

HeraMED Limited (ASX:HMD) ("HeraMED" or the "Company"), a medical data and technology company leading the digital transformation of maternity care, is pleased to announce a pilot agreement with Obstetrix Medical Group, an affiliate of Mednax. Listed on the NYSE, with a market capitalisation of over US\$2.2 billion, Mednax is one of the largest providers of women's and children's physician services in the U.S. via its network of over 2,300 physicians in 39 states and Puerto Rico. Mednax-affiliated clinicians and their practices provide vital care or diagnostics to 1 in 4 babies born in the U.S. Mednax companies and solutions include Pediatrix Medical Group, the nation's leading provider of maternal-fetal, newborn and pediatric subspecialty services, and Obstetrix Medical Group, a provider of obstetric and maternal-fetal services.

The paid pilot represents the initial part of the agreement, including the purchase of 100 licenses to the HeraCARE software and devices, and will evaluate the functionality and suitability of the technology of the HeraCARE platform. Upon completion of the pilot, both Obstetrix and HeraMED will seek to enter into a comprehensive agreement for wider deployment and scaled commercial implementation of the technology.

Since this pilot was first announced in May, HeraMED's customer success team has been working closely with Obstetrix to ensure the HeraCARE platform is fully integrated with the workflows and clinical pathways. Both parties have been focused on configuring and optimising the platform to accommodate Obstetrix's requirements, as well as providing training to the project's staff.

HeraMED CEO and Co-founder, Mr. David Groberman said: "The launch of the paid pilot represents a significant achievement, and I congratulate the HeraMED team for reaching this important milestone. We are already discussing extensions to this pilot with several new sites identified, and I am confident that today represents the start of a long history working with Obstetrix," he said.

About Obstetrix Medical Group

Obstetrix Medical Group, a Mednax affiliate, is a provider of obstetric and maternal-fetal services, dedicated to improving patient outcomes. Hospitals and clinicians partner with us to collaborate in the care of pregnant and laboring women through office and hospital-based maternal-fetal services and OB/GYN hospitalist programs.

As a national, multi-specialty medical group, our clinicians collaborate across the care continuum, from conception to birth and beyond, to deliver high-quality, evidence-based, cost-effective care. Our specialty-driven education and clinical programs support clinicians and hospitals in achieving better maternal and fetal outcomes while reducing care costs.

About Mednax

Mednax, Inc. is a national medical group comprised of the nation's leading providers of physician services. Physicians and advanced practitioners practicing as part of Mednax are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives, clinical research and telehealth programs to enhance patient outcomes and provide high-quality, cost-effective care. The Company was founded in 1979, and today, through its affiliated professional entities, Mednax provides services through a network of more than 2,300 physicians in 39 states and Puerto Rico. Additional information is available at www.mednax.com.

-ENDS-

This announcement has been authorised by the Board of HeraMED Limited.

HeraMED Limited

CEO and Co-Founder

David Groberman

M: +972 52 6991188

E: David@hera-med.com

Company Secretary

Jonathan Hart

T: +61 2 7251 1888

E: Jonathan@hera-med.com

Investors

Tim Chapman

PAC Partners

M: +61 419 897 062

E: tchapman@pacpartners.com.au

About HeraMED Limited (ASX:HMD)

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data, and a digital social networking dashboard.

About HeraCARE

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.